Recent Pfizer Press Releases

  • 10/23/14 4:05 pm EDT

    Board of Directors Authorizes New $11 Billion Share Repurchase Program

    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 26-cent fourth-quarter 2014 dividend on the company’s common stock, payable December 2, 2014, to shareholders of record at the close of business on November 7, 2014. The fourth-quarter 2014 cash dividend will be the 304th consecutive quarterly dividend paid by Pfizer. The board of directors also authorized a new $11 billion share repurchase program to be utilized over time. This newmore...
  • 10/23/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® (sunitinib malate) capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021. “The Court’s decision acknowledges the validity and infringement of ourmore...
  • 10/17/14 4:38 pm EDT

    EMBEDA is the first and only approved ER morphine specifically designed to deter oral and intranasal abuse when crushed

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has approved an updated label for EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, for oral use, CII, to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal (i.e., snorting) routes when crushed. However, abuse ofmore...
  • 10/13/14 8:00 am EDT

    NDA Requests Approval of Palbociclib as a First-Line Therapy in Combination with Letrozole for ER+, HER2- Advanced Breast Cancer

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). This NDA requests FDA approval of palbociclib, in combination with letrozole, as a first-line treatment for postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who havemore...
  • 10/10/14 8:00 am EDT

    Rapid and sustained response in functional antibody titers observed following single-dose administration of a novel, investigational 4-antigen Staphylococcus aureus vaccine (SA4Ag) to healthy adults

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it will present data from a Phase 1/Phase 2 study evaluating the safety, tolerability and immunogenicity of a single-dose vaccine of Pfizer’s investigational 4-antigen Staphylococcus aureus (S. aureus) candidate vaccine (SA4Ag) in healthy adults. The data will be presented at IDWeek 2014™ taking place Oct. 8-12, 2014 in Philadelphia, Pennsylvania. The SA4Ag vaccine candidate (PF-06290510),more...
  • 10/8/14 8:30 am EDT
    • Metastatic breast cancer currently affects 150,000-250,000 people in the U.S. and remains an incurable condition1,2
    • New initiative aims to expand the breast cancer conversation to be more inclusive of metastatic disease
    NEW YORK--(BUSINESS WIRE)--This October, Pfizer Inc. is uniting with leaders in the breast cancer community in a public call-to-action to expand the breast cancer dialogue to include metastatic breast cancer. This comes after a first-of-its-kind survey commissioned by Pfizer revealed that many people know little to nothing about metastatic breast cancer – the most advanced stage of breast cancer (Stage IV), in which cancer has spread beyond the breast to other organs inmore...
  • 10/8/14 8:00 am EDT

    Data From This Study Will Be Presented At IDWeek 2014™ In Philadelphia

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086 (rLP2086), with a licensed quadrivalent human papillomavirus vaccine (HPV4), at IDWeek 2014™ in Philadelphia. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086more...
  • 9/29/14 8:00 pm EDT

    Agreement to Combine Kyowa Hakko Kirin’s Anti-CCR4 Antibody Mogamulizumab and Pfizer’s investigational 4-1BB agonist (PF-05082566) in Clinical Study

    NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086 (rLP2086), with a licensed quadrivalent human papillomavirus vaccine (HPV4), at IDWeek 2014™ in Philadelphia. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086more...
  • 9/25/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions. “We believe this acquisition will help Pfizer build a strong sterile injectables pipeline in areas such as oncology and central nervous disordersmore...
  • 9/23/14 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 28, 2014. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2014 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizermore...